Interpreting cost-effectiveness in dialysis: Can the most expensive be more expensive?

Kidney International

Volumn 69, Issue 12, 2006, Pages 2120-2121

  McFarlane, P A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ANEMIA; COST EFFECTIVENESS ANALYSIS; DIALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEMODIALYSIS; HUMAN; KIDNEY ARTERIOVENOUS FISTULA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW;

EID: 33745066447     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001556     Document Type: Note

References (8)

1. Tonelli M, Klarenbach S, Jindal K, Manns B. Economic implications of screening strategies in arteriovenous fistulae. Kidney Int 2006; 69: 2219-2226.
2. Tonelli M, Winkelmayer WC, Jindal KK et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304.
3. McFarlane PA, Bayoumi AM. Acceptance and rejection: cost-effectiveness and the working nephrologist. Kidney Int 2004; 66: 1735-1741.
4. Laupacis A, Feeny D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-481.
5. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-717.
6. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should "reasonable decisions" lead to uncontrolled growth in expenditures? CMAJ 2003; 168: 849-851.
7. McFarlane PA. Reducing hemodialysis costs: conventional and quotidian home hemodialysis in Canada. Semin Dial 2004; 17: 118-124.
8. United States Renal Data System. Excerpts from the USRDS 2003 Annual Data Report: atlas of end-stage renal disease in the Unites States. Am J Kidney Dis 2003; 42(Suppl 5): S1-S230.